BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 9664292)

  • 1. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle.
    Jordan A; Hadfield JA; Lawrence NJ; McGown AT
    Med Res Rev; 1998 Jul; 18(4):259-96. PubMed ID: 9664292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of rhizoxin with bovine brain tubulin.
    Sullivan AS; Prasad V; Roach MC; Takahashi M; Iwasaki S; Ludueña RF
    Cancer Res; 1990 Jul; 50(14):4277-80. PubMed ID: 2364385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.
    Hamel E
    Pharmacol Ther; 1992; 55(1):31-51. PubMed ID: 1287674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new culture model facilitating rapid quantitative testing of mitotic spindle inhibition in mammalian cells.
    De Brabander M; Van de Veire R; Aerts F; Geuens S; Hoebeke J
    J Natl Cancer Inst; 1976 Feb; 56(2):357-63. PubMed ID: 1255766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.
    Bai RL; Pettit GR; Hamel E
    J Biol Chem; 1990 Oct; 265(28):17141-9. PubMed ID: 2211617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticancer substances of vegetable origin. Spindle poisons: vincaleukoblastine, leurocristine and navelbine; taxol and taxotere].
    Guéritte-Voegelein F; Guénard D; Potier P
    C R Seances Soc Biol Fil; 1992; 186(5):433-40. PubMed ID: 1363958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrotubular drugs binding to vinca domain of tubulin.
    Gupta S; Bhattacharyya B
    Mol Cell Biochem; 2003 Nov; 253(1-2):41-7. PubMed ID: 14619954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Microtubules and antineoplastic drugs].
    Arioka H; Saijo N
    Gan To Kagaku Ryoho; 1994 Apr; 21(5):583-90. PubMed ID: 7908790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhizoxin binding to tubulin at the maytansine-binding site.
    Takahashi M; Iwasaki S; Kobayashi H; Okuda S; Murai T; Sato Y
    Biochim Biophys Acta; 1987 Dec; 926(3):215-23. PubMed ID: 3120782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
    Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
    J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs.
    Prota AE; Bargsten K; Diaz JF; Marsh M; Cuevas C; Liniger M; Neuhaus C; Andreu JM; Altmann KH; Steinmetz MO
    Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13817-21. PubMed ID: 25114240
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antimitotic agents on tubulin-nucleotide interactions.
    Correia JJ
    Pharmacol Ther; 1991 Nov; 52(2):127-47. PubMed ID: 1818332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Inhibitors of tubulin assembly: specially on rhizoxin-maytansine site ligands].
    Iwasaki S
    Tanpakushitsu Kakusan Koso; 1993 Aug; 38(11):1742-52. PubMed ID: 8210422
    [No Abstract]   [Full Text] [Related]  

  • 14. Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data.
    Bai RL; Paull KD; Herald CL; Malspeis L; Pettit GR; Hamel E
    J Biol Chem; 1991 Aug; 266(24):15882-9. PubMed ID: 1874739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tubulins - the target for anticancer therapy.
    Vindya NG; Sharma N; Yadav M; Ethiraj KR
    Curr Top Med Chem; 2015; 15(1):73-82. PubMed ID: 25579568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biological characteristics of microtubule and related drug research].
    Li JN; Jiang JD
    Yao Xue Xue Bao; 2003 Apr; 38(4):311-5. PubMed ID: 12889136
    [No Abstract]   [Full Text] [Related]  

  • 17. Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain.
    Bai R; Pettit GR; Hamel E
    Biochem Pharmacol; 1990 Jun; 39(12):1941-9. PubMed ID: 2353935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinca site agents induce structural changes in tubulin different from and antagonistic to changes induced by colchicine site agents.
    Sackett DL
    Biochemistry; 1995 May; 34(21):7010-9. PubMed ID: 7766610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indirubin, a bis-indole alkaloid binds to tubulin and exhibits antimitotic activity against HeLa cells in synergism with vinblastine.
    Mohan L; Raghav D; Ashraf SM; Sebastian J; Rathinasamy K
    Biomed Pharmacother; 2018 Sep; 105():506-517. PubMed ID: 29883946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction of cryptophycin 1 with tubulin and microtubules.
    Kerksiek K; Mejillano MR; Schwartz RE; Georg GI; Himes RH
    FEBS Lett; 1995 Dec; 377(1):59-61. PubMed ID: 8543019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.